MX384973B - Regímenes de dosificación de inmunoconjugado anti-receptor 1 de folato (folr1). - Google Patents

Regímenes de dosificación de inmunoconjugado anti-receptor 1 de folato (folr1).

Info

Publication number
MX384973B
MX384973B MX2016004411A MX2016004411A MX384973B MX 384973 B MX384973 B MX 384973B MX 2016004411 A MX2016004411 A MX 2016004411A MX 2016004411 A MX2016004411 A MX 2016004411A MX 384973 B MX384973 B MX 384973B
Authority
MX
Mexico
Prior art keywords
folr1
dosing regimen
folate receptor
immunoconjugate
immunoconjugate dosing
Prior art date
Application number
MX2016004411A
Other languages
English (en)
Spanish (es)
Other versions
MX2016004411A (es
Inventor
Jose Ponte
Robert J Lutz
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384973(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2016004411A publication Critical patent/MX2016004411A/es
Publication of MX384973B publication Critical patent/MX384973B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016004411A 2013-10-08 2014-10-08 Regímenes de dosificación de inmunoconjugado anti-receptor 1 de folato (folr1). MX384973B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361888337P 2013-10-08 2013-10-08
US201361888365P 2013-10-08 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US201462004815P 2014-05-29 2014-05-29
PCT/US2014/059716 WO2015054400A2 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens

Publications (2)

Publication Number Publication Date
MX2016004411A MX2016004411A (es) 2016-07-05
MX384973B true MX384973B (es) 2025-03-14

Family

ID=52813740

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004411A MX384973B (es) 2013-10-08 2014-10-08 Regímenes de dosificación de inmunoconjugado anti-receptor 1 de folato (folr1).
MX2021009222A MX2021009222A (es) 2013-10-08 2016-04-06 Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009222A MX2021009222A (es) 2013-10-08 2016-04-06 Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).

Country Status (29)

Country Link
US (3) US20150132323A1 (OSRAM)
EP (3) EP4424323A3 (OSRAM)
JP (5) JP6463744B2 (OSRAM)
KR (7) KR102303874B1 (OSRAM)
CN (1) CN106164093A (OSRAM)
AU (4) AU2014331964C1 (OSRAM)
BR (1) BR112016007479A2 (OSRAM)
CA (1) CA2926325C (OSRAM)
CY (1) CY1122449T1 (OSRAM)
DK (2) DK3055332T3 (OSRAM)
ES (2) ES2759426T3 (OSRAM)
FI (1) FI3653228T3 (OSRAM)
HR (2) HRP20192140T1 (OSRAM)
HU (2) HUE046696T2 (OSRAM)
IL (4) IL298044B2 (OSRAM)
LT (2) LT3055332T (OSRAM)
MX (2) MX384973B (OSRAM)
MY (1) MY174670A (OSRAM)
NZ (2) NZ757964A (OSRAM)
PL (2) PL3653228T3 (OSRAM)
PT (2) PT3653228T (OSRAM)
RS (2) RS59644B1 (OSRAM)
RU (1) RU2696579C2 (OSRAM)
SG (3) SG10202102555TA (OSRAM)
SI (2) SI3653228T1 (OSRAM)
SM (1) SMT201900694T1 (OSRAM)
UA (1) UA119541C2 (OSRAM)
WO (1) WO2015054400A2 (OSRAM)
ZA (1) ZA201902009B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2831426C (en) * 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
CN104755498B (zh) 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
EP3625262A4 (en) * 2017-05-16 2021-03-03 ImmunoGen, Inc. ANTI-FOLR1 IMMUNE CONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
BR112020005212A2 (pt) 2017-09-18 2020-09-15 Sutro Biopharma, Inc. conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
MX2020009522A (es) 2018-03-13 2020-10-22 Phanes Therapeutics Inc Anticuerpos anti-folato del receptor 1 y usos de los mismos.
WO2020016661A2 (en) * 2018-07-09 2020-01-23 Multitude Inc. Antibodies specific to folate receptor alpha
CA3138272A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
TW202306995A (zh) * 2021-06-04 2023-02-16 美商免疫遺傳股份有限公司 治療具有可溶性ＦＲ－α之患者之癌症
EP4440625A1 (en) * 2021-12-01 2024-10-09 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
EP4455164A1 (en) * 2021-12-24 2024-10-30 Bio-Thera Solutions, Ltd. ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
CA2271464A1 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
US20080131366A1 (en) * 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
JP2008537778A (ja) * 2005-03-30 2008-09-25 パーデュー・リサーチ・ファウンデーション 細胞の葉酸ビタミン受容体の定量化による癌予後診断法
EP1937307A4 (en) * 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
RU2503687C2 (ru) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Сшивающие реагенты и их применение
DK2378876T3 (en) * 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
RU2012120691A (ru) * 2009-10-21 2013-11-27 Иммьюноджен, Инк. Новый режим дозирования и способ лечения
CN103037900B (zh) * 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
RU2630608C2 (ru) * 2010-11-05 2017-09-11 Морфотек Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
CA2831426C (en) 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
CN104755498B (zh) * 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
MX380565B (es) * 2013-04-08 2025-03-12 Berg Llc Terapias combinadas de coenzima q10 para el tratamiento de cáncer.
KR20240068778A (ko) * 2013-05-14 2024-05-17 이뮤노젠 아이엔씨 항-folr1 면역접합체 투약 섭생
US9637547B2 (en) * 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
IL257531B2 (en) * 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates

Also Published As

Publication number Publication date
EP3055332B1 (en) 2019-09-25
NZ718766A (en) 2020-02-28
EP3055332A2 (en) 2016-08-17
KR102115217B1 (ko) 2020-05-26
MX2016004411A (es) 2016-07-05
SG11201602361UA (en) 2016-04-28
KR20220136468A (ko) 2022-10-07
JP7386208B2 (ja) 2023-11-24
IL298044B2 (en) 2024-11-01
WO2015054400A3 (en) 2015-06-25
PT3653228T (pt) 2024-07-17
EP4424323A2 (en) 2024-09-04
AU2020264270B2 (en) 2024-01-18
MY174670A (en) 2020-05-06
RS65798B1 (sr) 2024-08-30
SG10201907042PA (en) 2019-09-27
AU2024201615A1 (en) 2024-04-04
HUE067367T2 (hu) 2024-10-28
EP3653228A1 (en) 2020-05-20
IL313730A (en) 2024-08-01
LT3055332T (lt) 2020-04-10
AU2014331964A1 (en) 2016-04-28
ZA201902009B (en) 2020-10-28
SI3055332T1 (sl) 2020-02-28
CA2926325C (en) 2023-08-01
PT3055332T (pt) 2019-12-09
RS59644B1 (sr) 2020-01-31
RU2016114708A3 (OSRAM) 2018-07-31
JP2021178847A (ja) 2021-11-18
CY1122449T1 (el) 2021-01-27
SI3653228T1 (sl) 2024-09-30
IL244772A0 (en) 2016-04-21
AU2014331964C1 (en) 2019-10-31
US20210155688A1 (en) 2021-05-27
JP2024016239A (ja) 2024-02-06
DK3653228T3 (da) 2024-07-15
EP4424323A3 (en) 2024-11-13
EP3653228B1 (en) 2024-05-15
HRP20240917T1 (hr) 2024-10-11
KR102639861B1 (ko) 2024-02-22
MX2021009222A (es) 2021-09-08
WO2015054400A2 (en) 2015-04-16
KR20240027861A (ko) 2024-03-04
EP3055332A4 (en) 2017-05-31
ES2983055T3 (es) 2024-10-21
KR20200058592A (ko) 2020-05-27
AU2020264270A1 (en) 2020-11-26
KR20230145544A (ko) 2023-10-17
IL244772B (en) 2019-05-30
BR112016007479A2 (pt) 2017-09-12
SMT201900694T1 (it) 2020-01-14
JP2019031568A (ja) 2019-02-28
CA2926325A1 (en) 2015-04-16
JP6581279B2 (ja) 2019-09-25
ES2759426T3 (es) 2020-05-11
KR102115217B9 (ko) 2021-12-24
JP2019218386A (ja) 2019-12-26
HUE046696T2 (hu) 2020-03-30
IL265586A (en) 2019-05-30
KR102303874B1 (ko) 2021-09-17
FI3653228T3 (fi) 2024-07-04
HRP20192140T1 (hr) 2020-03-06
RU2016114708A (ru) 2017-11-15
AU2014331964B2 (en) 2018-09-13
JP6463744B2 (ja) 2019-02-06
HK1226671A1 (en) 2017-10-06
AU2018278880A1 (en) 2019-01-03
IL298044A (en) 2023-01-01
DK3055332T3 (da) 2019-12-09
JP2016534039A (ja) 2016-11-04
CN106164093A (zh) 2016-11-23
KR20210041124A (ko) 2021-04-14
NZ757964A (en) 2022-07-01
UA119541C2 (uk) 2019-07-10
KR20160079797A (ko) 2016-07-06
SG10202102555TA (en) 2021-04-29
PL3055332T3 (pl) 2020-02-28
PL3653228T3 (pl) 2024-11-12
RU2696579C2 (ru) 2019-08-05
US20240368270A1 (en) 2024-11-07
US20150132323A1 (en) 2015-05-14
LT3653228T (lt) 2024-07-25
IL298044B1 (en) 2024-07-01
KR20210118220A (ko) 2021-09-29

Similar Documents

Publication Publication Date Title
MX2015015735A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
MX384973B (es) Regímenes de dosificación de inmunoconjugado anti-receptor 1 de folato (folr1).
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
PH12016501995A1 (en) Tubulysin derivatives
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
EA202092967A1 (ru) Схемы приема иммуноконъюгата антитела против cd37
WO2015175533A3 (en) Anti-cd37 immunoconjugate dosing regimens
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
MX2016011706A (es) Formulaciones de progesterona.
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MY203104A (en) Anti-folr1 immunoconjugate dosing regimens
EA201991330A1 (ru) Способы лечения рака с помощью антител к tim-3
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
EA201991336A1 (ru) Способы лечения рака с помощью антител к pd-1